secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K/A
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001628280-24-042879
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics appoints Paige Mahaney as CSO effective Oct 28; Stewart Fisher retires
--------------------------------------------------------------------------------

- Paige Mahaney, Ph.D., formerly SVP at Exelixis, appointed CSO effective October 28, 2024.
- Stewart Fisher, Ph.D., retires as CSO Oct 28, will serve as Senior Scientific Advisor through Dec 2024, then consultant through Dec 2025.
- Mahaney receives $510k base salary, $150k sign-on bonus, up to $75k relocation, and performance bonus up to 40% of base.
- Mahaney granted inducement option for 345,600 shares (25% vests at 1 yr, rest over 3 yrs) and RSUs for 76,800 shares (vest over 4 yrs).
- Fisher's retirement not due to any disagreement; consulting agreement provides continued equity vesting through Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024042879/0001628280-24-042879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024042879/cccc-20241015.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-042879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer